TBPH FINANCIAL STATEMENTS

Theravance Biopharma Inc — balance sheet, income statement and cash flow trends

TBPHTheravance Biopharma Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue109.8 M $+68.2%

Gross Profit88.2 M $+251.0%

Operating Income88 K $—

EBITDA142.5 M $—

Net Income114.5 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
TBPH	68.2%	80.4%	129.8%	104.3%
MSB	410.4%	-32.0%	-76.6%	-115.3%
TLX	56.3%	50.8%	3.0%	-0.9%
RTALB	24.0%	35.1%	9.0%	136.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
TBPH	68.2%	80.4%	129.8%	104.3%
MRVI	-15.4%	29.0%	-50.8%	-51.1%
FDMT	383,560.9%	-12.4%	-185.2%	-182.3%
SPRY	1.9%	77.1%	-194.1%	-200.0%
ZVRA	—	—	—	—
GERN	68.6%	86.6%	-18.8%	-35.5%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity290.6 M $62%
Current Liabilities31.8 M $7%
Long-term Liabilities149.9 M $32%

Key Figures

YoY change

Total Assets472.3 M $+37.5%

Total Liabilities181.7 M $+2.3%

Total Equity290.6 M $+75.1%

Cash & ST Investments394.7 M $+201.6%

Total Debt73.3 M $+52.2%

Net Debt-214.8 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
TBPH	13.14	25.2%	-2.26	61.5%
MSB	—	—	—	—
TLX	1.43	112.3%	13.13	35.1%
RTALB	1.21	1.2%	0.90	84.9%
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
TBPH	13.14	25.2%	-2.26	61.5%
MRVI	5.91	128.0%	-1.01	29.7%
FDMT	9.34	4.5%	2.27	88.1%
SPRY	4.94	157.4%	0.54	21.3%
ZVRA	4.89	0.6%	—	73.9%
GERN	6.78	109.9%	1.69	42.9%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow268.8 M $+726.4%

Capital Expenditures42 K $-82.6%

Free Cash Flow268.7 M $+732.4%

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
TBPH	244.8%	244.8%	0.0%	234.7%
MSB	-87.7%	-90.0%	2.3%	76.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
RTALB	58.5%	88.6%	10.8%	42.9%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
TBPH	244.8%	244.8%	0.0%	234.7%
MRVI	-19.3%	-25.3%	6.0%	37.8%
FDMT	-146.7%	-147.4%	0.9%	80.5%
SPRY	-176.9%	-177.1%	0.3%	88.4%
ZVRA	—	—	—	—
GERN	-64.2%	-64.4%	0.3%	181.0%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on TBPH

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.